
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc reports a strong positive outlook driven by significant revenue growth anticipated from its Signatera minimal residual disease (MRD) testing, with Q3 reflecting a record increase of 21,500 tests quarter-over-quarter and a remarkable 54% year-over-year growth. The company has indicated potential for expanding reimbursement coverage across various cancer types, which is expected to enhance average selling prices (ASP), gross margins, and operating cash flow. Additionally, Natera has revised its 2025 revenue guidance upward by $160 million, following a robust revenue beat of approximately $80 million in Q3, reinforcing confidence in its growth trajectory.
Bears say
Natera faces a negative outlook primarily due to anticipated margin erosion stemming from reduced in-network pricing, as more commercial payors are expected to join the market and the total addressable market expands to include average risk patients. Compression of average selling prices (ASPs) for its Panorama product is also a significant concern, which could further impact profitability. Additionally, ethical concerns surrounding the use of its patented technology and potential reluctance from patients to utilize genetic tests could hinder Natera's growth prospects in the competitive diagnostics landscape.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares